Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
Taiwan
· Delayed Price · Currency is TWD 36.40
-0.45 (-1.22%)
Mar 9, 2026, 1:35 PM CST
Nang Kuang Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,162 | 2,200 | 2,150 | 1,940 | 1,780 | Upgrade
|
| Revenue Growth (YoY) | -1.71% | 2.31% | 10.81% | 9.01% | 1.44% | Upgrade
|
| Cost of Revenue | 1,393 | 1,452 | 1,395 | 1,246 | 1,186 | Upgrade
|
| Gross Profit | 768.86 | 747.79 | 755.56 | 694.9 | 594.47 | Upgrade
|
| Selling, General & Admin | 302.62 | 270.88 | 252.78 | 227.29 | 204.05 | Upgrade
|
| Research & Development | 170.58 | 169.36 | 164.11 | 143.81 | 133.97 | Upgrade
|
| Operating Expenses | 473.19 | 437.57 | 495.72 | 373.24 | 339.99 | Upgrade
|
| Operating Income | 295.67 | 310.22 | 259.84 | 321.67 | 254.48 | Upgrade
|
| Interest Expense | -8.59 | -5.53 | -7.18 | -4.84 | -3.53 | Upgrade
|
| Interest & Investment Income | 3.12 | 3 | 10.64 | 2.69 | 3.46 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 8.6 | 4.1 | 8.79 | -11.98 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.94 | 9.82 | 9.44 | 9.25 | 10.04 | Upgrade
|
| EBT Excluding Unusual Items | 291.14 | 326.11 | 276.85 | 337.56 | 252.47 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -23.07 | -1.85 | 73.11 | 0.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.17 | 6.1 | -0.05 | -0.15 | Upgrade
|
| Legal Settlements | - | - | -67.43 | - | -22.96 | Upgrade
|
| Other Unusual Items | - | - | 0 | - | 5.26 | Upgrade
|
| Pretax Income | 291.14 | 303.2 | 213.68 | 410.63 | 234.76 | Upgrade
|
| Income Tax Expense | 47.2 | 59.8 | 15.27 | 58.63 | 38.65 | Upgrade
|
| Earnings From Continuing Operations | 243.95 | 243.41 | 198.41 | 352 | 196.11 | Upgrade
|
| Minority Interest in Earnings | 0.47 | - | - | - | - | Upgrade
|
| Net Income | 244.41 | 243.41 | 198.41 | 352 | 196.11 | Upgrade
|
| Net Income to Common | 244.41 | 243.41 | 198.41 | 352 | 196.11 | Upgrade
|
| Net Income Growth | 0.41% | 22.68% | -43.63% | 79.49% | 6.93% | Upgrade
|
| Shares Outstanding (Basic) | 101 | 101 | 101 | 101 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 101 | 101 | 101 | 101 | Upgrade
|
| Shares Change (YoY) | 0.16% | 0.10% | -0.08% | -0.01% | 0.03% | Upgrade
|
| EPS (Basic) | 2.42 | 2.41 | 1.96 | 3.49 | 1.94 | Upgrade
|
| EPS (Diluted) | 2.41 | 2.40 | 1.96 | 3.48 | 1.94 | Upgrade
|
| EPS Growth | 0.42% | 22.45% | -43.68% | 79.38% | 7.18% | Upgrade
|
| Free Cash Flow | 186.25 | -58.17 | 45.1 | 275.35 | 400.58 | Upgrade
|
| Free Cash Flow Per Share | 1.84 | -0.57 | 0.45 | 2.72 | 3.96 | Upgrade
|
| Dividend Per Share | - | 1.600 | 2.000 | 2.300 | 1.800 | Upgrade
|
| Dividend Growth | - | -20.00% | -13.04% | 27.78% | 12.50% | Upgrade
|
| Gross Margin | 35.56% | 33.99% | 35.14% | 35.81% | 33.40% | Upgrade
|
| Operating Margin | 13.67% | 14.10% | 12.08% | 16.58% | 14.30% | Upgrade
|
| Profit Margin | 11.30% | 11.06% | 9.23% | 18.14% | 11.02% | Upgrade
|
| Free Cash Flow Margin | 8.61% | -2.64% | 2.10% | 14.19% | 22.50% | Upgrade
|
| EBITDA | 478.81 | 492.34 | 440.76 | 496.66 | 433.33 | Upgrade
|
| EBITDA Margin | 22.14% | 22.38% | 20.50% | 25.59% | 24.34% | Upgrade
|
| D&A For EBITDA | 183.14 | 182.12 | 180.92 | 174.99 | 178.85 | Upgrade
|
| EBIT | 295.67 | 310.22 | 259.84 | 321.67 | 254.48 | Upgrade
|
| EBIT Margin | 13.67% | 14.10% | 12.08% | 16.58% | 14.30% | Upgrade
|
| Effective Tax Rate | 16.21% | 19.72% | 7.15% | 14.28% | 16.46% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.